CAS |
114798-26-4 |
Chinese Name |
洛沙坦 |
English Name |
Losartan |
Synonym |
氯沙坦;科索亚;洛沙坦;络沙坦; |
Unit |
Bottle |
Purity |
≥98% |
Molecular Formula |
C22H23ClN6O |
Molecular Weight |
422.91 |
Appearance |
White to off-white solid |
Storage |
Powder : 2-8℃, 2 years; In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in DMSO |
EC |
EINECS 601-329-8 |
MDL |
MFCD00865831 |
InChIKey |
PSIFNNKUMBGKDQ-UHFFFAOYSA-N |
InChI |
InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28) |
PubChem CID |
3961 |
SMILES |
OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2 |
Description |
Losartan is an angiotensin II receptor antagonist that competes with angiotensin II for binding to the AT1 receptor. |
Target Point |
Angiotensin Receptor |
Passage |
GPCR & G Protein |
Data Literature Source |
[1]. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation, 2001. 103(6): p. 904-12.
[2]. Ashry, O., et al. Evidence for expression and function of angiotensin II receptor type 1 in pulmonary epithelial cells. Respir Physiol Neurobiol, 2014.
[3]. Choi, C.H., et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol, 2012. 126(1): p. 124-31.
[4]. Habashi, J.P., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006. 312(5770): p. 117-21.
[5]. Campbell, D.J., et al. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol, 1995. 26(2): p. 233-40. |
Specification |
100mg 200mg 500mg 1g |